Integra LifeSciences Introduces InterFix Radiosurgery Kit for Use With TomoTherapy Radiation Treatment Systems

PLAINSBORO, N.J., Feb 28, 2008 (PrimeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that its subsidiary, Integra Radionics, Inc., has launched the InterFix(TM) Radiosurgery Kit for use with TomoTherapy(R) radiation treatment systems. The InterFix(TM) Radiosurgery Kit provides a way to adapt the existing Integra Radionics(TM) stereotactic hardware to the TomoTherapy(R) Hi-Art(R) system for stereotactic treatment of cranial tumors and vascular malformations. The InterFix(TM) Radiosurgery Kit has received FDA clearance in the United States, as well as CE Mark Certification in the European Union.

Integra Radionics has a long history in stereotactic surgery, with the CRW(TM) stereotactic system for neurosurgery, and the XKnife(TM) system for stereotactic radiosurgery. Its research and development team worked extensively with TomoTherapy to develop a means to utilize the industry-leading Radionics(TM) stereotactic tools with the Hi-Art(TM) treatment system.

Stereotactic radiosurgery is a minimally invasive technique used to deliver a single high dose of radiation to small, well-defined target volumes, while avoiding nearby normal tissue and critical structures. The targeted volumes are primarily brain tumors and vascular malformations.

"We are pleased with the design of the Radionics InterFix(TM) solution from Integra. Our initial evaluation indicates it will provide the consistent repositioning and rigid immobilization needed for performing radiosurgery with the TomoTherapy system. We are glad to have been able to contribute to the design and look forward to using it clinically," stated Wolfgang A. Tome, Ph.D., Associate Professor, University of Wisconsin School of Medicine and Public Health.

"TomoTherapy has developed a unique and advanced radiation delivery system that has gained wide acceptance," said Jason D. Ellnor, director of marketing for Integra's stereotactic products. "We are thrilled with the opportunity to combine our world leading stereotactic hardware with this exciting and growing technology."

Both the TomoTherapy(TM) sales force and distributors and the Integra NeuroSciences direct sales organization will sell the InterFix(TM) Radiosurgery Kit worldwide. Integra NeuroSciences is a leading provider of implants, devices, instruments and systems used in neurosurgery, neuromonitoring, neuro-trauma, and related critical care. Integra NeuroSciences' direct selling effort in the United States and Europe involves more than 200 direct sales professionals. In all other markets, Integra NeuroSciences products are sold through a network of distributors.

TomoTherapy Incorporated (Nasdaq:TOMO) develops, manufactures and sells the TomoTherapy(R) Hi-Art(R) treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi-Art treatment system combines integrated CT imaging with helical intensity modulated radiation therapy to deliver sophisticated treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. www.tomotherapy.com

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. The company's products are used to treat millions of patients every year, primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery. Integra's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. www.Integra-LS.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the InterFix(TM) Radiosurgery Kit and the TomoTherapy(R) radiation treatment systems. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in section IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2006 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART-P

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation
John B. Henneman, III, Executive Vice President, Chief
Administrative Officer, Acting Chief Financial Officer
(609) 936-2481
jhenneman@Integra-LS.com
Gianna Sabella, Public Relations Manager
(609) 936-2389
gsabella@integra-LS.com